Citizens raised the firm’s price target on Prelude Therapeutics (PRLD) to $6 from $3 and keeps an Outperform rating on the shares following the Q4 report. The preclinical JAK2V617F data support potential best-in-class selectivity and disease modifying potential, the analyst tells investors in a research note. Citizens believes Prelude shares “represent a unique investment opportunity with meaningful upside.”
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
